Ithaka Group LLC lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 0.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,416 shares of the medical device company’s stock after purchasing an additional 703 shares during the quarter. Ithaka Group LLC owned approximately 0.09% of DexCom worth $5,956,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. FMR LLC boosted its position in shares of DexCom by 9.1% in the 1st quarter. FMR LLC now owns 9,845,408 shares of the medical device company’s stock valued at $834,201,000 after purchasing an additional 823,406 shares during the period. Vanguard Group Inc. boosted its position in shares of DexCom by 4.2% in the 1st quarter. Vanguard Group Inc. now owns 6,596,294 shares of the medical device company’s stock valued at $558,904,000 after purchasing an additional 263,543 shares during the period. Baillie Gifford & Co. boosted its position in shares of DexCom by 1.4% in the 1st quarter. Baillie Gifford & Co. now owns 6,212,889 shares of the medical device company’s stock valued at $526,418,000 after purchasing an additional 84,085 shares during the period. BlackRock Inc. boosted its position in shares of DexCom by 5.5% in the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock valued at $321,232,000 after purchasing an additional 230,542 shares during the period. Finally, Janus Capital Management LLC boosted its position in shares of DexCom by 12.2% in the 1st quarter. Janus Capital Management LLC now owns 4,001,971 shares of the medical device company’s stock valued at $339,083,000 after purchasing an additional 436,162 shares during the period.

DXCM has been the subject of a number of research analyst reports. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Robert W. Baird reissued a “hold” rating and issued a $79.00 target price on shares of DexCom in a research report on Sunday, September 10th. Cowen and Company reissued a “buy” rating and issued a $90.00 target price on shares of DexCom in a research report on Friday, July 14th. BMO Capital Markets reissued a “buy” rating and issued a $105.00 target price on shares of DexCom in a research report on Thursday, July 13th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $78.00 target price on shares of DexCom in a research report on Monday, May 22nd. Seven equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $86.87.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/09/19/dexcom-inc-dxcm-shares-bought-by-ithaka-group-llc.html.

Shares of DexCom, Inc. (NASDAQ DXCM) traded down 1.31% during trading on Tuesday, hitting $68.35. The stock had a trading volume of 403,750 shares. The firm’s 50-day moving average is $72.53 and its 200-day moving average is $73.94. The firm’s market cap is $5.92 billion. DexCom, Inc. has a one year low of $57.68 and a one year high of $94.79.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The business’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Equities research analysts forecast that DexCom, Inc. will post ($0.78) EPS for the current year.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total transaction of $113,375.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $71.86, for a total value of $431,160.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 26,223 shares of company stock worth $1,881,249. Corporate insiders own 1.70% of the company’s stock.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.